Table 4.
Multivariable analysis for factors associated with biochemical progression-free survival
| Variable | Comparison | HR (95% CI) | P value |
|---|---|---|---|
| Age | 1.03 (1.001–1.05) | .04 | |
| T stage | Tx vs T1/2 | 0.35 (0.08–1.50) | .16 |
| T3/4 vs T1/2 | 1.33 (0.90–2.00) | .15 | |
| N stage | Nx vs N0 | 1.40 (0.54–3.57) | .49 |
| N1 vs N0 | 2.00 (1.12–3.55) | .02 | |
| M stage | Mx vs M0 | 0.86 (0.55–1.35) | .51 |
| M1 vs M0 | 0.44 (0.23–0.83) | .01 | |
| Gleason grade group | 1.01 (0.83–1.24) | .91 | |
| iPSA | 1.002 (1.0008–1.003) | <.001 | |
| ADT | Yes vs No | 0.41 (0.26–0.67) | <.001 |
| Number met | 0.99 (0.83–1.20) | .94 | |
| Tx location | Bone vs Node | 1.42 (0.93–2.17) | .11 |
| Multiple vs Node | 0.50 (0.22–1.12) | .09 | |
| Pre-SABR PSA | 1.02 (1.01–1.04) | .01 | |
| Enhanced imaging | 2.81 (1.55–5.12) | .001 |
Abbreviations: ADT = androgen deprivation therapy; CI = confidence interval; HR = hazard ratio; iPSA = initial PSA; PSA = prostate-specific antigen; Tx= treatment.